Samsung Bioepis and Yuhan Collaborate for the Commercialization of Adalloce (biosimilar, adalimumab) in Korea

Shots:

Samsung Bioepis enter into a marketing collaboration with Yuhan Corporation for the domestic sale of Adalloce in Korea to treat RA, AS, and CD
Additionally, Samsung Bioepis is conducting domestic sales of Etoloce (biosimilar, enbrel) and Remaloce (biosimilar, Remicade), which have been previously released, through Yuhan Corporation
Based on the contract, the cooperation between the two companies can be further strengthened

Click here to read full press release/ article | Ref: Samsung Bioepis | Image: Samsung Bioepis